Djokovic bets on a COVID cure as he quests for tennis history
21 January, 2022, 9:13 am
COPENHAGEN, Jan 19 (Reuters) – The pandemic has blocked Novak Djokovic’s march to tennis history, so the 34-year-old may be pinning his hopes on a cure for COVID to get his hands on another glorious grand slam before time runs out.
The Serbian superstar, who became a focus of the global vaccine debate over his failed attempt to enter Australia without being inoculated, holds a majority stake in a Danish biotech firm aiming to develop a treatment to counter COVID-19, the company’s CEO told Reuters. read more
The company is developing a peptide, which inhibits the coronavirus from infecting the human cell, expects to launch clinical trials in Britain this summer, according to Loncarevic, who stressed the firm was working on a treatment, not a vaccine.
A spokesperson for Djokovic did not immediately respond to a request for comment.
Djokovic has enjoyed phenomenal success – Forbes listed him in the world’s top-50 highest paid athletes for 2021. It calculated his on-court earnings at $4.5 million, dwarfed by the $30 million it said he earned off court.
He had desperately hoped to play in Australian Open this month with his sights firmly set on netting a 21st grand slam title, which would move him above archrivals Roger Federer and Rafa Nadal.
Frustrated Djokovic now risks being frozen out of tennis, with rules on travellers who are unvaccinated tightening in the third year of the pandemic and some tournaments reconsidering exemptions.
The most immediate concern is the next grand slam – the French Open in May where Nadal has already amassed a staggering 13 titles – after the country’s sports ministry said on Monday there would be no exemption from a new vaccine pass law.